PDF(Pubmed)
Abstract：
Retinal degenerative disorders (RDDs) cause vision loss by damaging retinal neurons and photoreceptors, affecting individuals of all ages. Cell-based therapy has emerged as an effective approach for the treatment of RDDs with promising results. This meta-analysis aims to comprehensively evaluate the efficacy of cell therapy in treating age-related macular degeneration (AMD), retinitis pigmentosa (RP), and Stargardt macular degeneration (SMD) as the most prevalent RDDs.
PubMed, Scopus, Web of Science, and Embase were searched using keywords related to various retinal diseases and cell therapy treatments until November 25th, 2023. The studies\' quality was evaluated using the Joanna Briggs Institute\'s (JBI) checklist for quasi-experimental studies. Visual acuity measured as LogMAR score was used as our main outcome. A three-level random-effect meta-analysis was used to explore the visual acuity in patients who received cell-based therapy. Heterogeneity among the included studies was evaluated using subgroup and sensitivity analyses. Moreover, meta-regression for the type of cells, year of publication, and mean age of participants were performed.
Overall, 8345 studies were retrieved by the search, and 39 met the eligibility criteria, out of which 18 studies with a total of 224 eyes were included in the meta-analysis. There were 12 studies conducted on AMD, 7 on SMD, and 2 on RP. Cell therapy for AMD showed significant improvement in LogMAR (p < 0.05). Also, cell therapy decreased the LogMAR score in SMD and RP (p < 0.01 and p < 0.0001, respectively). Across all conditions, no substantial publication bias was detected (p < 0.05).
The findings of the study highlight that the application of cell therapy can enhance the visual acuity in AMD, SMD, and RP.
PubMed, Scopus, Web of Science, and Embase were searched using keywords related to various retinal diseases and cell therapy treatments until November 25th, 2023. The studies\' quality was evaluated using the Joanna Briggs Institute\'s (JBI) checklist for quasi-experimental studies. Visual acuity measured as LogMAR score was used as our main outcome. A three-level random-effect meta-analysis was used to explore the visual acuity in patients who received cell-based therapy. Heterogeneity among the included studies was evaluated using subgroup and sensitivity analyses. Moreover, meta-regression for the type of cells, year of publication, and mean age of participants were performed.
Overall, 8345 studies were retrieved by the search, and 39 met the eligibility criteria, out of which 18 studies with a total of 224 eyes were included in the meta-analysis. There were 12 studies conducted on AMD, 7 on SMD, and 2 on RP. Cell therapy for AMD showed significant improvement in LogMAR (p < 0.05). Also, cell therapy decreased the LogMAR score in SMD and RP (p < 0.01 and p < 0.0001, respectively). Across all conditions, no substantial publication bias was detected (p < 0.05).
The findings of the study highlight that the application of cell therapy can enhance the visual acuity in AMD, SMD, and RP.
摘要：
背景：视网膜退行性疾病（RDDs）通过损害视网膜神经元和光感受器而导致视力丧失，影响所有年龄段的人。基于细胞的疗法已成为治疗RDD的有效方法，并取得了有希望的结果。这项荟萃分析旨在全面评估细胞疗法治疗年龄相关性黄斑变性（AMD）的疗效。视网膜色素变性（RP），Stargardt黄斑变性（SMD）是最常见的RDD。
方法：PubMed，Scopus,WebofScience,和Embase使用与各种视网膜疾病和细胞治疗相关的关键词进行搜索，直到11月25日，2023年。使用JoannaBriggs研究所（JBI）的准实验研究清单评估研究质量。以LogMAR评分测量的视力被用作我们的主要结果。使用三级随机效应荟萃分析来探索接受基于细胞的治疗的患者的视力。使用亚组和敏感性分析评估纳入研究之间的异质性。此外，细胞类型的元回归，出版年份,和参与者的平均年龄进行。
结果：总体而言，通过搜索检索了8345项研究，39人符合资格标准，其中18项研究共224只眼纳入荟萃分析.有12项关于AMD的研究，7在SMD上，2在RP上。AMD的细胞疗法显示LogMAR的显著改善(p<0.05)。此外，细胞治疗降低了SMD和RP的LogMAR评分（分别为p<0.01和p<0.0001）。在所有条件下，未检测到实质性发表偏倚(p<0.05).
结论：研究结果突出表明，细胞疗法的应用可以提高AMD的视力，SMD,和RP。
方法：PubMed，Scopus,WebofScience,和Embase使用与各种视网膜疾病和细胞治疗相关的关键词进行搜索，直到11月25日，2023年。使用JoannaBriggs研究所（JBI）的准实验研究清单评估研究质量。以LogMAR评分测量的视力被用作我们的主要结果。使用三级随机效应荟萃分析来探索接受基于细胞的治疗的患者的视力。使用亚组和敏感性分析评估纳入研究之间的异质性。此外，细胞类型的元回归，出版年份,和参与者的平均年龄进行。
结果：总体而言，通过搜索检索了8345项研究，39人符合资格标准，其中18项研究共224只眼纳入荟萃分析.有12项关于AMD的研究，7在SMD上，2在RP上。AMD的细胞疗法显示LogMAR的显著改善(p<0.05)。此外，细胞治疗降低了SMD和RP的LogMAR评分（分别为p<0.01和p<0.0001）。在所有条件下，未检测到实质性发表偏倚(p<0.05).
结论：研究结果突出表明，细胞疗法的应用可以提高AMD的视力，SMD,和RP。
